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Virion infectivity factor (Vif) facilitates HIV infection by counteracting APOBEC3G late in replication in virus-producer cells. Here, we show
that early after infection of new target cells Vif is part of the HIV reverse transcription machinery and acts as an accessory factor for reverse
transcription. Vif protein was present in gradient fractions containing reverse transcription complexes (RTCs), and anti-Vif antibody
immunoprecipitated HIV reverse transcription products from these gradient fractions. To investigate a role for Vif in RTCs independent of
APOBEC3G, we created an intracellular environment that would restrict reverse transcription by pre-treating permissive target cells with 5-Fluoro
2-deoxyuridine, a thymidylate synthetase inhibitor, prior to infection with virus from permissive cells. Infectivity assays and quantitation of
reverse transcription products demonstrated that replication of HIV lacking Vif was inhibited to a greater degree than wild type, without
concurrent mutation of reverse transcription products, suggesting compromised reverse transcription in the absence of Vif.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV; Vif; Reverse transcription complex; RTC; Reverse transcription; Pre-integration complex; FdUrdIntroduction
The human immunodeficiency virus (HIV) virion infectivity
factor (Vif) is essential for efficient viral replication in natural
target cells (Gabuzda et al., 1992; Sova et al., 1995; von
Schwedler et al., 1993). A major function of Vif is to prevent the
action of APOBEC3G, a cellular inhibitor of HIV replication
(Sheehy et al., 2002), or other APOBEC3 family members such
as APOBEC3F (Zheng et al., 2004). APOBEC3 enzymes are
cytosine deaminases that, in the absence of Vif, deaminate C toU
residues in newly synthesised HIV minus strand DNA, leading
to G–Amutation in the HIV proviral DNA (Cullen, 2006; Harris
et al., 2003; Lecossier et al., 2003; Mangeat et al., 2003; Zhang
et al., 2003). In viral producer cells, Vif induces degradation of⁎ Corresponding author. Infectious Diseases Laboratories, Institute of Medical
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doi:10.1016/j.virol.2007.10.041and inhibits virion incorporation of APOBEC3G, thus prevent-
ing its inhibitory actions on HIV replication in subsequent target
cells (Kao et al., 2003b; Mariani et al., 2003; Marin et al., 2003;
Sheehy et al., 2003; Yu et al., 2003).
However, broader biological roles of Vif in HIV infection
remain to be fully explored. Whilst some reports describe that
virions produced in the absence of Vif have normal viral protein
and RNA content (Bouyac et al., 1997; Fouchier et al., 1996;
Gaddis et al., 2003; Ochsenbauer et al., 1997; von Schwedler
et al., 1993), others describe abnormal virion morphology and
less stable virion cores (Borman et al., 1995; Ohagen and
Gabuzda, 2000; Sakai et al., 1993). Virus particles from Vif-
deficient HIV enter target cells normally but are defective in
production or accumulation of reverse transcription products
(Courcoul et al., 1995; Nascimbeni et al., 1998; Simon and
Malim, 1996; Sova and Volsky, 1993; von Schwedler et al.,
1993). This well described observation may relate to the actions
of APOBEC3G that in the absence of Vif can induce mutation in
reverse transcription products (Harris et al., 2003; Lecossier
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transcription (Guo et al., 2006). However, inhibition of reverse
transcription in the absence of Vif might also reflect a direct
effect of the lack of Vif on the reverse transcription process. This
is supported by studies that have detected Vif in HIV virions
(Fouchier et al., 1996; Kao et al., 2003a; Karczewski and
Strebel, 1996; Khan et al., 2001) and the observed enhancement
by Vif of reverse transcription in vitro (Cancio et al., 2004;
Henriet et al., 2007).
Following virus entry into a target cell, an active reverse
transcription complex (RTC) forms. HIV RTCs are large
nucleoprotein complexes containing viral proteins, matrix
(MA), NC, integrase (IN), Vpr, protease (PR) and reverse
transcriptase (RT) (Bukrinsky et al., 1993; Farnet and Haseltine,
1991; Fassati and Goff, 2001; Karageorgos et al., 1993; Miller
et al., 1997). When isolated from cells lysed in either detergent
or hypotonic conditions, RTCs do not contain p24, although
p24 has been visualised in association with RTCs in living cells
(McDonald et al., 2002) and it has been recently suggested that
reverse transcription may occur within a p24 shell (Arhel et al.,
2007). In this study we have investigated the presence of Vif in
HIV RTCs and its potential function during the early reverse
transcription process. We demonstrate by co-immunoprecipita-
tion that Vif is physically associated with reverse transcription
products in RTCs and show that Vif protein co-sediments with
RTCs. In the absence of APOBEC3G or other factors from non-
permissive cells, reverse transcription by Vif-deficient (Δvif)
HIV was compromised to a greater degree than wild type (WT)
virus in target cells that had been treated with 5-Flouro, 2-
deoxyuridine (FdUrd), a pyrimidine analogue that alters cellular
dNTP levels (Jackson, 1978). Our results thus suggest that Vif is
part of the early HIV replication machinery and enhances the
reverse transcription process when it is occurring under less
than optimal conditions. Thus Vif action may be particularly
relevant in cell types or biological situations that are important
in HIV pathogenesis in vivo but are not modelled in con-
ventional laboratory HIV culture systems.
Results
HIV Vif co-precipitates with reverse transcription products in
RTCs
Infection was initiated using a highly productive one-step
synchronous cell-to-cell infection model, involving mixing of
infected donor cells (H3B; a clone of H9 cells persistently
infected with HTLV-IIIB in which there is minimal extrachro-
mosomal HIV DNA or active reverse transcription) with un-
infected recipient Hut-78 cells. This results in a burst of newHIV
reverse transcription and DNA synthesis (Li and Burrell, 1992).
Following infection cells were lysed, immunoprecipitated with
Vif or control antibodies and DNA was extracted from
precipitated complexes and analysed for HIV reverse transcrip-
tion products. Early and late reverse transcription products were
precipitated by a rabbit polyclonal Vif antibody but not with the
pre-immune sera control (Fig. 1A). A monoclonal Vif antibody
also co-precipitated U5/gag DNA at 6 h pi confirming that HIVreverse transcription products specifically co-precipitate with
Vif. The quantitative difference in immunoprecipitation using
different antibodies and at different time points post infection
(pi) may reflect different antibody binding ability or accessibility
of the Vif protein in the RTC. In separate experiments to validate
the immunoprecipitation technique, HIV reverse transcription
products were co-precipitated by an anti-IN but not p24
antibody, consistent with reports that RTCs contain IN but not
p24 under these conditions (Bukrinsky et al., 1993; Karageorgos
et al., 1993) (data not shown). In a similar way we attempted to
immunoprecipitate newly synthesised reverse transcription
products using a Vif antibody following WT and ΔVif infec-
tions. However, these experiments required initiation of infec-
tion using cell-free virus and the results were inconclusive due to
the lower levels of reverse transcription products present in
infection with cell-free virus. To examine whether Vif was
associated with other known RTC components we analysed
whether Vif antibody could co-precipitate RT activity. Cells
were lysed and immunoprecipitated, as above with pre-immune
sera, Vif and IN polyclonal antibody. The immunoprecipitates
were assayed for their ability to catalyse RT-PCR of an exog-
enous RNA substrate (in vitro transcribed dengue virus [DV]
RNA) and compared with RT-PCR reactions performed with
AMV RT, the initial HIV infected cell lysate or no RT enzyme
control. Both Vif and IN antibodies but not pre-immune sera
successfully immunoprecipitated RT-PCR activity (Fig. 1B).
Thus, in newly infected cells Vif was associated with both newly
synthesised reverse transcription products and RT enzyme
activity, two essential components of an active RTC.
We next wished to test whether reverse transcription prod-
ucts could also be co-immunoprecipitated with Vif after
gradient fractionation of RTCs. Our laboratory has previously
established and validated a system for gradient isolation of HIV
RTCs (Carr et al., 2006; Karageorgos et al., 1993). Lysates from
infected cells were harvested at 6 h pi and fractionated on
sucrose velocity gradients and the fractions were analysed for
three known RTC properties: (i) the presence of newly
synthesised reverse transcription products, (ii) the presence of
endogenous RT activity, and (iii) velocity sedimentation rate.
Fractions were also subjected to immunoprecipitation using pre-
immune sera or HIV Vif antibody. Before immunoprecipitation,
in vitro endogenous RT activity peaked in fr 4–5 (Fig. 2A),
whilst ssDNAwas more broadly distributed and peaked in fr 5–
6 (1.08–1.09 g/ml sucrose) consistent with the sedimentation
rate of HIV RTCs (Carr et al., 2006; Karageorgos et al., 1993).
ssDNA that was specifically precipitable by Vif antibody was
more sharply confined to frs 5 and 6 only (Fig. 2B). Similarly,
U5-gag DNA, a marker of later reverse transcription, was
distributed broadly across the gradient, peaking in fr 5–6 and
was specifically precipitated by Vif antibody from fr 6 only. The
lack of precipitation of U5-gag DNA from fr 5 by Vif antibody
may be due to loss or inaccessibility of Vif protein in the later
U5-gag containing RTC structures in fr 5. Together these results
indicate that structures sedimenting at a rate characteristic for
RTCs and containing both reverse transcription products and
RT enzyme activity also contain HIV Vif protein. To confirm
the association between Vif protein and RTCs further, RTCs
Fig. 1. Vif co-precipitates with HIV reverse transcription products and RT activity from total cell lysates. Hut-78 cells were infected by cell mixing with HIV infected
H3B cells and the cells were lysed and immunoprecipitated with rabbit pre-immune serum, Vif rabbit polyclonal Ab (pAb), Vif monoclonal (mAb) or IN rabbit
polyclonal antibody (IN). (A) DNAwas extracted from precipitates and analysed for ssDNA or U5/gag DNA by real time PCR. Values represent mean±SEM (n=2)
determined from copy numbers standards run in parallel. (B) Precipitated proteins were analysed for RT activity by RT-PCR of in vitro transcribed DV RNA. RT
reactions were performed with 5 μl of immunoprecipitated proteins from reactions with rabbit pre-immune sera (pre), HIV IN rabbit polyclonal antibody (IN) and HIV
Vif polyclonal antibody (Vif). Control RT reactions were performed with AMVRT (AMV), 5 μl of the unprecipitated lysate from HIV infected cells (lysate) or without
enzyme (neg). RT activity is presented as copy number of DV RNA quantitated by real time PCR.
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influenced by shape, size and density and were then further
purified on a sucrose equilibrium gradient, which separates
according to density. We have previously shown that authentic
RTCs (identified by the presence of RT activity, newly syn-Fig. 2. Vif co-precipitates with HIV RTCs isolated on sucrose velocity gradients. Hut-7
and subjected to 15–30% rate zonal sucrose gradient fractionation at 35,000 rpm for 5
RTactivity by in vitro 3H-TTP incorporation or (C) U5-gag DNA by PCR. The same f
pAb and the precipitates were analysed for (B) ssDNA or (D) U5-gag DNA by PCR. V
copy numbers standards run in parallel.thesised reverse transcription products and IN protein) band at
1.21–1.22 g/ml sucrose under these conditions (Carr et al.,
2006). We took the RTC-containing fractions banding in
this second gradient at 1.20–1.24 g/ml sucrose (fr 7–9) and
containing reverse transcription products and performed8 cells were infected by mixing with HIV infected H3B cells, cells lysed at 6 h pi
0 min. Gradient fractions were analysed for (A) ssDNA by PCR and endogenous
ractions were also immunoprecipitated with rabbit pre-immune sera or rabbit Vif
alues for ssDNA or U5-gag DNA represent mean±SEM (n=2) determined from
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DNA) reverse transcription products in the major RTC fraction
at 1.22 g/ml sucrose were co-precipitated by Vif antibody
(Fig. 3) thereby confirming that the association between Vif and
RTCs remains after more extensive purification of RTCs.
We next examined directly whether Vif protein could be
detected in these immunoprecipitating fractions and if the
sedimentation of Vif in these fractions was dependent on the
presence of active reverse transcription and the presence of
RTCs. The sedimentation of Vif protein alone without the
presence of other HIV proteins was assessed by sucrose
gradient fractionation and Western blot of a cell lysate from 293
cells transfected with a Vif expression vector (pCMV-Vif myc)Fig. 3. Vif co-precipitates with HIV reverse transcription products sedimenting
at the density of RTCs isolated on sucrose equilibrium gradients. Hut-78 cells
were infected by mixing with HIV infected H3B cells, cells lysed at 6 h pi and
subjected to 15–30% rate zonal sucrose gradient fractionation at 35,000 rpm for
50 min. Gradient fractions were analysed for ssDNA and U5-gag DNA by PCR
(A). Fraction 5, with peak ssDNA/U5-gag DNA levels and sedimenting at the
same density as RTCs from which Vif previously co-precipitated reverse
transcription products (Fig. 2), was further purified by 10–70% sucrose
equilibrium gradient centrifugation at 26,000 rpm for 18 h. Gradient fractions
were analysed for ssDNA and U5-gag DNA by PCR (B) and immunopreci-
pitated with rabbit pre-immune sera or rabbit Vif polyclonal anti-sera and the
precipitates were analysed for ssDNA and U5-gag DNA (C). Values for ssDNA
or U5-gag DNA represent mean±SEM (n=2) determined from copy numbers
standards run in parallel.(Feng et al., 2004). Vif protein was detected at the top of the
gradient (fr 1) and in the sucrose cushion (fr10), but not within
the gradient where RTCs are found (Fig. 4A). Next, to assess the
velocity sedimentation of Vif protein in the presence of other
HIV proteins but in the absence of active reverse transcription,
chronically infected H3B cells were mixed with uninfected Hut-
78, lysed immediately (0 h) and subjected to sucrose velocity
gradient sedimentation and Western blot. At 0 h pi Vif was
distributed at the top of the gradient (fr 2–5) and p24 overlapped
with this with a slightly broader distribution (fr 1–5; Fig. 4B.2)
whilst as previously described (Li and Burrell, 1992) no sig-
nificant reverse transcription products were present (Fig. 4B.1).
These findings are likely to represent Vif-containing HIV
assembly complexes derived from the chronically infected H3B
cells. When the cultures were incubated for 6 h after cell mixing
before harvesting to allow the onset of reverse transcription,
ssDNA and Vif proteins were present in frs 1–6 with a peak
together in fr 3–4. U5/gag DNA was in a more discrete and
more rapidly sedimenting structure in frs 4–6. In contrast to the
results at 0 h, the distribution of p24 protein did not directly
overlap with Vif but was maximal at the top of the gradient
(Fig. 4C.1 and 2). These results suggest that (i) Vif protein and
reverse transcription products can both be detected at a
sedimentation velocity (1.08–1.09 g/ml sucrose) from which
we have shown successful co-immunoprecipitation of reverse
transcription products with Vif antibody and (ii) that Vif and
p24 proteins are present in complexes prior to reverse
transcription, and upon activation of reverse transcription, the
majority of Vif remains in complexes but the majority of p24 is
lost and sediments as free protein. These findings further
demonstrate that Vif is an integral part of HIV RTCs.
An additional function of Vif in HIV reverse transcription
independent of APOBEC3G
Earlier studies have demonstrated that Vif-deficient (Δvif)
virus can replicate normally in permissive cells. However, the
intracellular environment within HIV target cells is well known
to influence the efficiency of viral replication. We thus aimed to
assess the function of Vif in early HIV infection in a target cell
environment that did not contain APOBEC3G but was
constrained for normal viral replication for other reasons. This
situation was produced by pre-treating permissive (i.e. APO-
BEC3G negative) target cells with a low concentration of the
uridine analogue FdUrd. This agent inhibits thymidylate
synthase resulting in the disruption of the normal cellular
balance of dNTPs, with elevated levels of dUTP and decreased
dTTP (Jackson, 1978). The concentration(s) of FdUrd used were
in the nanomolar range which was non-cytotoxic over the
duration of the experiment (data not shown) and was less than
the micrometer concentration range generally employed to
induce DNA mutation and cell death (Meyers et al., 2005).
The permissive indicator cell line HeLaCD4 LTR-βgal was
pre-treated with FdUrd and infectivity assays were performed
with WT and ΔVif virus that had been produced from
permissive CEM-SS cells and thus would not contain any
APOBEC3G incorporated within virions. A dose dependent
Fig. 4. Vif is present in RTC-containing gradient fractions from cells undergoing active reverse transcription. (A) Sedimentation of Vif in the absence of other HIV
proteins. A total cell lysate from 293 cells transfected with a Vif expression plasmid was subjected to sucrose velocity gradient sedimentation, in 15–30% sucrose at
35,000 rpm for 50 min and fractions analysed for Vif protein by Western blot. (B) Sedimentation of Vif in the absence of reverse transcription. Infections were initiated
by mixing of HIV infected H3B and uninfected Hut-78, the cells were lysed at 0 h in 0.05% Triton X-100 and cytoplasmic lysates subjected to sucrose velocity gradient
sedimentation. Fractions were collected from the top of the gradient and analysed for ssDNA or U5/gag DNA by real time PCR (B.1). Values represent mean±SEM
(n=2) from copy numbers determined from standards run in parallel. Fractions were also analysed for Vif and p24 protein by Western blot (B.2). (C) Sedimentation of
Vif in the presence of active reverse transcription. Cells were infected as for (B), cultured for 6 h then lysed, velocity sedimented and analysed for ssDNA or U5/gag
DNA by real time PCR (C.1) and Vif and p24 protein by Western blot (C.2), as in (B). Fraction numbers are indicated from 1 (top) to 11 (bottom) of the sucrose
gradient.
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marked restriction of ΔVif than WT infection at all doses tested
(Fig. 5A). Analysis at a single FdUrd concentration showed that
infectivity of ΔVif was reproducibly and significantly inhibitedFig. 5. Increased inhibition of ΔVif HIV infectivity by FdUrd in an HIV
infectivity assay. Permissive HeLaCD4 LTR-βgal cells were pre-incubated 2 h
before infection±FdUrd and infected with WT or ΔVif NL4.3 derived from
amplification in permissive CEM-SS cells using equivalent levels of p24. After
48 h incubation with or without FdUrd, the cells were fixed and stained for β-gal
and blue cells enumerated by light microscopy. Values were normalised against
number of blue cells seen without FdUrd. A=FdUrd dose response. Results
shown are from a single experiment. Values represent av±SEM from duplicate
infection wells; B=average infectivity values±50 nM FdUrd from replicate
experiments (n=3). Values represent mean±SEM. Values were compared by
Student's t-test and p values are indicated.approximately 40% further than that observed for WT HIV
(Fig. 5A, B).
We next assessed if the greater inhibition of Vif-deficient
HIV infection in the presence of FdUrd was due to restriction of
reverse transcription. Permissive CEM-SS cells were pre-
treated with 50 nM FdUrd and infected with WT or ΔVif
virus, as above. Extrachromosomal DNAwas extracted at early
time points pi and reverse transcription products quantitated.
Consistent with the infectivity data, results showed a reduction
in levels of first strand transfer reverse transcription products by
FdUrd inΔVif compared with WT HIV infection (Fig. 6A) with
a significant and reproducible 40% greater inhibition of reverse
transcription from ΔVif virus at 10 h pi (Fig. 6B).
The greater degree of inhibition of reverse transcription of
Vif-deficient virus by FdUrd may be a consequence of greater
frequency of FdUrd-induced mutation or reduced efficiency of
the reverse transcription process itself. We investigated this by
sequence analysis of the early reverse transcription products
produced in the presence of FdUrd. The nef-LTR region
(706 bp), representing products following first strand transfer,
was amplified from early reverse transcription products
(unintegrated DNA) at 10 h post infection using a high fidelity
polymerase, cloned and sequenced. Analysis of 6 independent
clones from reverse transcription products derived following
ΔVif+50 nM FdUrd infection showed 5 clones with 0/706 bp
Fig. 6. Reduction of HIV infectivity by FdUrd is accompanied by reduced
reverse transcription. Permissive CEM-SS cells were infected by centrifugal
enhancement with equivalent p24 levels of WT and ΔVif NL4.3 derived from
amplification in permissive CEM-SS cells. Following infection cells were
trypsinised, washed and cultured. A=at 2 h and 10 h pi cells were counted, lysed
and extrachromosomal DNA extracted and analysed for HIV reverse
transcription products by real time PCR. Values=av±SEM, n=2. Results
represent a single experiment that was replicated. B=values+50 nM FdUrd
were expressed relative to values obtained without drug. Results represent
average values±SEM, from replicate experiments (n=3). Values were compared
by Student's t-test and p values are indicated.
152 J.M. Carr et al. / Virology 372 (2008) 147–156mutations and 1 clone with 4/706 G–A substitutions, showing
very fewDNA sequence substitutions whilstWT+50 nMFdUrd
showed no mutations (0/1412 bp, data not shown). Similarly,
sequencing of 6 clones fromΔVif+5 nM FdUrd, which still has
an inhibitory effect on ΔVif replication (Fig. 5A), showed no
sequence mutations. Thus ΔVif infection+FdUrd which is
associated with restricted reverse transcription in the absence
of APOBEC3G showed a distinctly lower mutation frequency
(4/8472 or 0.05%) compared to the rate (2.4%) we previously
observed for ΔVif infection of non-permissive Hut-78 cells that
is associated with the presence of APOBEC3G (Carr et al.,
2006). Since sequencing of multiple independent clones failed to
identify hypermutation of cytoplasmic reverse transcription
products fromΔVif virus in the presence of FdUrd, this suggests
that the reduction of reverse transcription and infectivity in this
situation was directly due to reduced efficiency rather than
fidelity of the reverse transcription process.
Discussion
In this study we have shown that the accessory protein Vif is
part of the HIV replication machinery during early reverse
transcription and can act as an accessory factor to promote
reverse transcription and viral infectivity.
We identified RTCs in this study based on sucrose velocity
gradient sedimentation, the presence of RT activity and newly
synthesised HIV reverse transcription products and also by the
presence of IN protein as shown in previous experiments from
our laboratory (Carr et al., 2006; Karageorgos et al., 1993). We
observed co-sedimentation of Vif protein with RTCs and co-
precipitation of HIV reverse transcription products using a Vif
antibody, from either infected cell lysates or gradient fractions
containing RTCs indicating a true physical association of Vif
within RTCs. Notably, Vif antibody immunoprecipitated a moresharply sedimenting major subset of RTCs, suggesting that RTC
structures display heterogeneity in size, composition and pos-
sibly in function and that Vif may have a specific function in
some RTCs only. Previous work in our laboratory was unable to
detect Vif in RTCs by immunoprecipitation (Karageorgos et al.,
1993). This earlier study examined RTC-containing fractions at
a single sucrose density only, potentially omitting the RTC
fraction of interest, whilst the study described here utilises
different Vif antibodies and a more sensitive and quantitative
PCR detection method.
The presence of Vif as part of RTCs in newly infected cells
carries the prerequisite that Vif is present in virions. Although
Vif can be non-specifically incorporated into murine leukaemia
virus (MLV) virions and has not been detected in HIV virion
preparations in some earlier studies (Camaur and Trono, 1996;
Dettenhofer and Yu, 1999; Sova et al., 2001), other studies have
identified Vif as part of HIV virions. The failure to detect Vif in
virions reported in some instances may be due to intravirion
proteolysis of Vif and/or lower levels of Vif virion incorporation
from chronically infected cell lines (Camaur and Trono, 1996;
Kao et al., 2003a; Karczewski and Strebel, 1996; Khan et al.,
2001, 2002). Results of the present study support the view that
Vif is part of the virion and has a functional requirement in the
newly infected cell.
Although Vif-deficient virions are not grossly aberrant
morphologically, there is evidence that they have altered
physical and biochemical properties. Some studies have reported
Vif-deficient virions to have altered core structure and reduced
core stability (Borman et al., 1995; Bouyac et al., 1997; Ohagen
and Gabuzda, 2000). Previous studies have also suggested that
Vif-deficient virus has reduced ability for endogenous reverse
transcription (Dettenhofer et al., 2000) although again this
observation is not seen in all studies (Gaddis et al., 2003).
Biochemical transcription studies using recombinant proteins
have suggested that Vif facilitates RT–primer binding and RT
activity in vitro (Cancio et al., 2004). Further recent data based
on in vitro assays have shown that Vif may act as a chaperone for
the early steps of reverse transcription by binding RNA,
enhancing tRNAlys3 primer annealing and increasing the
processivity of RT (Henriet et al., 2007). Thus, Vif within the
RTC may directly promote reverse transcription or, in a similar
manner to its role in core stability, may stabilise the RTC in the
target cell, either by physically contributing to the tertiary
structure required for efficient reverse transcription or by
protecting reverse transcription products from host anti-viral
defences such as APOBEC3G/F. However, such a role for Vif
has previously been given little attention and its main docu-
mented role has been preventing the incorporation of APOBEC3
enzymes into virions and the subsequent anti-viral actions of
APOBEC in newly infected target cells during reverse
transcription. Virus produced from cells lacking APOBEC3G
replicates normally in some cell lines, even in the absence of Vif,
which led to the view that the defective phenotype of Vif-
deficient virus is mediated by the action of APOBEC3G rather
than the loss of other important accessory functions of Vif.
However, these experiments measured HIV replication under
optimally permissive in vitro replication conditions. Whether
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intracellular environment is not as conducive to viral replication,
i.e. situations where any accessory functions could become
important, has not been investigated. We have mimicked this
situation by treating cells with a pyrimidine analogue that
inhibits pyrimidine biosynthesis and disrupts the balance of
cellular dNTP levels. Under these conditions we found that
infectivity and reverse transcription of Vif-deficient virus were
impaired to a greater extent than that of WT HIV. The effect was
not associated with increased mutation of reverse transcription
products that could result from increased dNTP misincorpora-
tion or reduced DNA repair in the absence of Vif. Thus the
greater impairment in reverse transcription of Vif-deficient virus
compared to WT virus in the presence of FdUrd appears to be
due to reduced efficiency rather than loss of fidelity of reverse
transcription in the absence of Vif.
These results show for the first time a biological difference in
intracellular reverse transcription of Vif-deficient comparedwith
WT virus in permissive target cells, consistent with the pre-
viously observed stimulation by Vif of reverse transcription in
vitro.When combinedwith our data showingVif is part of RTCs,
these results show both appropriate localisation and a functional
role for Vif in reverse transcription. Thus, Vif can act in twoways
to ensure efficient HIV infection of target cells (1) by preventing
the actions of anti-viral APOBEC enzymes and (2) by promoting
the reverse transcription process per se. This latter activity may
be particularly relevant in cell types or biological situations that
are important in HIV pathogenesis in vivo but are not modelled
in conventional laboratory HIV culture systems.
Materials and methods
Cells and plasmids
Hut-78 and CEM-SS cells were obtained from the NIH AIDS
Research and Reference Reagent Program (NIH AR&RRP).
H3B cells are a laboratory clone of H9 cells persistently infected
with HTLV-IIIB, as described previously (Li and Burrell, 1992).
pNL4.3 was obtained from the NIHAR&RRP. pNL4.3Δvif was
generated by NdeI/PflMI digestion of the SpeI/EcoRI fragment
of pNL4.3, end filling and re-ligation. The SpeI/EcoRI fragment
containing Δvif was sub-cloned back into pNL4.3 to regenerate
a full-length infectious clone, similar to previous Vif mutants
(Karczewski and Strebel, 1996; Khan et al., 2001). This
mutation generates a frame shift at amino acid 28 of Vif and
creates a stop codon at amino acid 40 resulting in a severely
truncated Vif protein but does not affect the neighbouring Vpr
open reading frame.
Virus stocks
NL4.3 or Vif-defective (Δvif) NL4.3 virus was derived by
transfection of 293 cells and amplification of virus supernatant
in CEM-SS. Virus stocks were DNase I treated and filtered
(0.22 μM) to remove contaminating DNA and cells. TCID50
was determined by titrating virus on CEM-SS cells. p24 content
of virus stocks was determined by ELISA (Roche).Cell–cell HIV infection
For cell-to-cell transmission of HIV, virus infected donor
cells (H3B) and uninfected recipient cells (Hut-78) were co-
cultured at a ratio of 1:4 (donor:recipient) at a density of
2×106 cell/ml, as previously described, achieving a highly
synchronous one-step infection (Li and Burrell, 1992).
Cell lysis and gradient fractionation of lysates
At 6 h pi cells were harvested, trypsinised, washed and lysed
for 15 min at room temperature in lysis buffer A (10 mM Tris,
pH 7.4, 150 mM KCl, 5 mM MgCl2, 1 mM DTT, 20 μg/ml
Aprotinin [LBA]) containing 0.1% Triton X-100, as previously
described (Carr et al., 2006; Karageorgos et al., 1993). Nuclei
were pelleted (2500×g, 5 min), supernatants clarified by
centrifugation (10,000×g, 10 min) and the resultant cytoplasmic
extracts were adjusted to 8% (w/v) sucrose, 0.5% (v/v) Triton
X-100 and stored at −80 °C before analysis. Cell lysates (1–5%
gradient volume) were fractionated on a 10 ml linear 15–30%
sucrose velocity gradient with 60% sucrose cushion in LBA
containing 0.5% Triton X-100 at 4 °C. Sucrose velocity
gradients were centrifuged in a SW40 rotor (Beckman) at
35,000 rpm for 50 min. One milliliter fractions were collected
from the top of the gradient and sucrose density determined by
refractive index. Sucrose equilibrium gradient sedimentation
was performed on a 10 ml linear 10–70% sucrose gradient and
centrifuged at 28,000 rpm for 18 h.
Real time PCR for HIV reverse transcription products
Gradient fractions or immunoprecipitates were treated with
proteinase K and extracted with phenol chloroform, and the
nucleic acid was precipitated with ethanol for subsequent real
time PCR analysis. Samples were analysed by real time PCR for
viral strong stop (ss), 1st strand transfer (ST) or U5-Gag DNA.
Reactions utilised primers pairs CTAACTAGGGAACC-
CACTGC and CTGCTAGAGATTTTCCACAC (ss DNA),
GAGCCCTCAGATCCTGCATA and TCCCTAGTTAGCCA-
GAGAGC (1st ST DNA) and GGTAACTAGAGATCCCT-
CAG and AGAGCTCCTCTGGTTTCCCT (U5-Gag DNA).
Reactions were performed using Syber green PCR mix (Qiagen)
and amplified by real time PCR cycling with a Rotor-gene 3000
(Corbett Research). Viral DNA copy numbers were determined
from genomic DNA standards derived from a mix of the H3B,
ACH2 and 8E5 chronically HIV-infected cell lines and ranged
from 3000 to 30 copies (Vandegraaff et al., 2001).
Immunoprecipitation (IP) of HIV reverse transcription products
and RT activity
Total cell lysates or sucrose gradient fractions from 1×108
cell equivalents were divided and incubated with rabbit pre-
immune sera (negative control), Vif antisera (rabbit anti-sera
raised in-house against recombinant Vif or Vif mAb TG002,
#2746, AR&RP) or IN antisera (mix of rabbit antisera #756,
757, 758, AR&RP) rotating for 3 h at 4 °C. Equilibrated protein
154 J.M. Carr et al. / Virology 372 (2008) 147–156A sepharose (1/20th the volume) was then added and the lysate
incubated for a further 1 h at 4 °C. Protein antibody complexes
were precipitated by centrifugation and washed five times in
cold LBA containing 0.5% Triton X-100, with vortexing in
between each wash. For analysis of HIV reverse transcription
products, DNA associated with the precipitated proteins was
extracted by proteinase K digestion, phenol chloroform extrac-
tion and ethanol precipitation and analysed for HIV DNA by
real time PCR. For analysis of HIV RT activity, immunopre-
cipitated proteins were resuspended in AMV reaction buffer
(Roche) and 1/10th the immunoprecipitate utilised in a reverse
transcription reaction with 20 ng of in vitro transcribed dengue
virus type 2 (DV) positive strand capsid RNA and primer Tag-
3.2 (Wati et al., 2007). Positive controls were performed with
1 U of AMV reverse transcriptase (Roche) and 5 μl of the
unprecipitated HIV infected cell lysate. Negative control reac-
tions were also performed with no RT enzyme. Tag primed-DV
cDNA was then subjected to 40 cycles of real time PCR
amplification as described previously (Wati et al., 2007) and
equivalent copy number DV RNA determined as a quantitative
measure of the amount of input RT enzyme activity.
RT assay
Endogenous RT assays were performed by methyl-3H-TTP
incorporation as described previously (Karageorgos et al.,
1993).
Western blot analysis
Total protein from sucrose gradient fractions was precipitated
at 4 °C by addition of 1/10th volume 100% (w/v) trichloroacetic
acid (TCA, Sigma Corp). The precipitated protein was
resuspended in 62.5 mM Tris, 2% SDS, 5% glycerol, pH 6.8
and 0.07%β-mercaptoethanol and subjected to denaturing SDS–
PAGE in 25 mM Tris, 192 mM glycine, 0.1% SDS with a 4%
stacking and 12.5% separating gel. Separated proteins were
transferred to a nitrocellulosemembrane, blocked in Tris buffered
saline containing 0.1% (v/v) Tween-20 (TBS-T) and 5% skim
milk powder and then probed with rabbit anti-Vif antibody
(#2221; NIH AIDS Research and Reference Reagent Program,
AR&RP, 1/6000) or rabbit anti-p24 antibody (#6458, NIH
AR&RP, 1/500). Membranes were then incubated with anti-
rabbit IgG–HRP secondary antibody conjugates, and the proteins
were visualised by chemiluminescence (GE Healthsciences).
Infectivity assays
Infectivity assays were performed as previously described
(Feng et al., 2004; Kimpton and Emerman, 1992). Briefly,
HeLaCD4LTR-β-gal cells were plated in 24 well plates at
1.5×104/well. Twenty four hours later supernatant was
removed and cells were left untreated or pre-treated with 5-
Flouro, 2-deoxyuridine (FdUrd, Sigma) at the indicated
concentration for 2 h. Medium was removed and cells were
infected with 100 ng p24 in a volume of 100 μl cell culture
medium±FdUrd for 2 h. Medium was removed, 300 μl freshmedium with half the original concentration of FdUrd added
and cells cultured. At 48 h post infection medium was removed,
cells fixed and stained for β-gal and blue cells enumerated
under light microscopy.
Analysis of early HIV reverse transcription
CEM-SS cells were left untreated or pre-treated with 50 nM
FdUrd for 2 h prior to infection. Cells were inoculated with
20 ng p24/106 cells of WT or ΔVif virus by centrifugal
enhancement, as above. At 2 h pi (immediately after centrifugal
enhancement procedure) and 10 h pi, 2×106 cells were
harvested and extrachromosomal DNA extracted according to
the Hirt method (Hirt, 1967; Vandegraaff et al., 2001). Early
reverse transcription products were quantitated by real time
PCR.
Cloning and sequencing of early reverse transcription products
Extrachromosomal DNA from cells taken at 10 h post
infection was amplified by PCR using Platinum Taq high
fidelity DNA polymerase (Invitrogen) and primer pair CACA-
CACAAGGCTACTTCCC and GCCTACTCCCCAGTC-
CCGCCCAGG. The PCR product was cloned by TA cloning
(TOPO cloning kit, Invitrogen) and sequenced using universal
and reverse sequencing primers (Big Dye Terminator, Applied
Biosystems).
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